Latest News and Blogs

The American Journal of Human Genetics has published its Genomic Medicine Year in Review for 2020, which includes a study featuring Congenica.

Dr. Muthu Meyyappan appointed Chief Commercial Officer (CCO), of Congenica. Based in Boston, MA, Muthu will lead Congenica’s global market expansion.

Congenica appoints Dr. Sam Roberts as Non-Executive Director to the Board. Sam is the Managing Director of Health & Care at Legal & General.

A recent study has shown that the Congenica platform demonstrated a superior role identifying the genetic causes of platelet-related bleeding disorders

New Funds to Drive Further Commercialisation of Rare and Inherited Cancer Applications and Expansion into Oncology, Wellness and Pharma Collaborations

Congenica's response to the UK Government's national genomic healthcare strategy, setting out its vision to extend the UK’s leadership in genomics

Congenica's new module accelerates research into the relationship between an individual’s genomic variation & COVID-19 susceptibility & clinical outcomes.

Congenica launches an update that will provide automated classification, evidence and reporting of recurrent ‘known’ variants, significantly saving time.

Congenica launches Congenica Prenatal, a new application that facilitate faster, more accurate and comprehensive molecular research into fetal anomalies.

Genomics England has announced a major new sequencing project to uncover how a person’s genetic make-up influences their susceptibility to COVID-19.

With case loads increasing every day, clinical teams are experiencing increasing pressure to make their variant interpretation more efficient.

Our Response To Coronavirus COVID-19 - Congenica